IPG-ALLOPURINOL TABLET

Pajjiż: Kanada

Lingwa: Ingliż

Sors: Health Canada

Ingredjent attiv:

ALLOPURINOL

Disponibbli minn:

MARCAN PHARMACEUTICALS INC

Kodiċi ATC:

M04AA01

INN (Isem Internazzjonali):

ALLOPURINOL

Dożaġġ:

200MG

Għamla farmaċewtika:

TABLET

Kompożizzjoni:

ALLOPURINOL 200MG

Rotta amministrattiva:

ORAL

Unitajiet fil-pakkett:

30/1000

Tip ta 'preskrizzjoni:

Prescription

Żona terapewtika:

ANTIGOUT AGENTS

Sommarju tal-prodott:

Active ingredient group (AIG) number: 0103654002; AHFS:

L-istatus ta 'awtorizzazzjoni:

APPROVED

Data ta 'l-awtorizzazzjoni:

2016-03-29

Karatteristiċi tal-prodott

_ _
_IPG-Allopurinol PM _
_ _
_Page 1 of 26 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION PR
IPG-ALLOPURINOL
Allopurinol Tablets
Tablets, 100, 200 and 300 mg, oral
USP
Xanthine Oxidase Inhibitor
Marcan Pharmaceuticals Inc.
2 Gurdwara Road, Suite #112
Ottawa, Ontario K2E 1A2
Date of Initial Authorization:
OCT 22, 2012
Date of Revision:
MAY 13, 2022
Submission Control Number: 258941
_ _
_IPG-Allopurinol PM _
_ _
_Page 2 of 26 _
RECENT MAJOR LABEL CHANGES
3 Serious Warnings and Precautions Box
05/2022
4 Dosage and Administration, 4.2 Recommended Dose and Dosage
Adjustment
05/2022
7 Warnings and Precautions
05/2022
7 Warnings and Precautions, 7.1.4 Geriatrics
05/2022
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
.............................................................................................
2
TABLE OF CONTENTS
................................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................................
4
1
INDICATIONS
................................................................................................................
4
1.1
Pediatrics
............................................................................................................
4
1.2
Geriatrics.............................................................................................................
4
2
CONTRAINDICATIONS
...................................................................................................
4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
.............................................................. 5
4
DOSAGE AND ADMINISTRATION
...................................................................................
5
4.2
Recommended Dose and Dosage
Adjustment....................................................... 5
4.5
Missed Dose
..........................................